Contemporary Treatment Options for Prostate Cancer

This CME activity has expired. You may still view the program content, however, you will not be able to obtain CME/CE credit.

CME/CE Information

Course Overview

In back-to-back publications in JAMA, two research teams reported patient-reported outcomes and quality of life in two separate populations of men with localized prostate cancer managed with contemporary treatment options. Treatment options included radical prostatectomy, external beam radiotherapy (EBRT), brachytherapy, and active surveillance. Because these treatment options all have nearly 100% 5-year survival, the research teams focused on patient-reported disease-specific functional outcomes and health related quality of life.

Across the two studies, each treatment strategy was associated with a distinct pattern of adverse effects in the 2 to 3 years after treatment. The findings of these studies are particularly important because they examine effects on patient functional outcomes and quality of life in large populations outside of clinical trials and focus on contemporary treatment options.

Healthcare providers play a critical role to engage in the shared decision-making conversation with patients facing management decisions when faced with localized prostate cancer.

Educational Objectives

At the conclusion of this activity, the participant should be able to:

  • Identify the key components of shared decision-making relevant to localized prostate cancer (i.e., risk of cancer progression, comparative oncologic effectiveness, comparative harms, patient preferences)
  • Summarize the comparative harms of contemporary external beam radiation therapy, radical prostatectomy, and active surveillance with respect to patient-reported functional outcomes (i.e., urinary, sexual, bowel, and hormonal side effects of treatment)
  • Discuss the recent data on modern radical prostatectomy and radiotherapy to inform patient decision-making regarding PSA screening and prostate cancer treatment
  • Describe the mission and role of Patient-Centered Outcomes Research Institute (PCORI) in assisting patient-centered outcomes research to support decision-making by patients, clinicians, and other healthcare providers
  • Practice shared decision making as a treatment team in the management of localized prostate cancer, incorporating patient preferences with what is known about risk of disease progression, functional outcomes, general quality of life outcomes and oncologic outcomes with each management option

Target Audience

This online enduring material is designed to meet the educational needs of primary care physicians, urologists, nurses, nurse practitioners, physician assistants, and pharmacists.

Method of Participation

This online activity is comprised of three presentations: 2 didactic presentations, 1 panel discussion, references, and a posttest.

To obtain CME/CE credit you should:

  • View the presentations in this enduring material.
  • Complete the posttest.
  • Complete and submit the registration and evaluation forms.

The estimated time to complete this activity, including review of the materials, is 1.25 hours.

Fee: There is no fee for this activity.

Hardware/software requirements: A computer with broadband internet access and speakers is required. Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.

If you have questions about the participation process, please e-mail the Office of Continuing Medical Education, or phone 713-798-8237.

Accreditation/Credit Designation


Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Academy of Family Physicians (AAFP)

This Enduring Material activity, Contemporary Treatment Options for Prostate Cancer, has been reviewed and is acceptable for up to 1.25 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/26/2018. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Assistants

This program has been reviewed and is approved for a maximum of 1.25 hours of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Approval is valid for one year from the issue date of October 1, 2017. Participants may submit the posttest at any time during that period.

This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

Successful completion of the posttest is required to earn Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70 percent correct.


The University of Texas Houston Health Science Center at Houston School of Nursing is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

This course is approved for 1.25 contact hour(s) of Nursing Continuing Education. The course is sponsored by the Office of Continuing Nursing Education at The University of Texas Health Science Center at Houston School of Nursing.


Houston Methodist Hospital is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Participants documenting activity completion by viewing the slides, passing the learning assessment, and completing an online evaluation within 45 days will receive 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit as a knowledge-based activity (UAN: 0478-9999-17-016-H01-P).

Term of Approval

Release Date: October 1, 2017 | Expiration Date: October 1, 2018

Peer Review

In September 2017, this continuing medical education online enduring material was reviewed by Jonathan Bergman, MD, Assistant Professor of Urology, UCLA School of Medicine, Los Angeles, California. To ensure the continued scientific relevance of this enduring material, its content will be reviewed again in September 2018.

Disclosure: Jonathan Bergman, MD: Nothing to disclose.

Program Director

Program Director
Dov Kadmon, MD
Professor of Urology
Baylor College of Medicine
Houston, Texas

Disclosure: Nothing to disclose.


This CME/CE activity is designed for use by healthcare professionals for educational purposes only. Information and opinion offered by the contributors represent their viewpoints. Conclusions drawn by the participant should be derived from careful consideration of all available scientific information. Prescription information and use of medical devices should be undertaken only after confirmation of information by consulting the FDA-approved uses and information.

Baylor College of Medicine makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Links are provided to other Internet sites solely for the convenience of users. Once you link to another site, you are subject to the site's terms and conditions of use including copyright and licensing restrictions.


The Office of Continuing Medical Education (OCME) makes every effort to develop CME/CE activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support℠, Baylor College of Medicine (BCM) has implemented a mechanism requiring everyone in a position to control the content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships: 1) at the time of the activity or within 12 months prior; and 2) of their spouses/partners.

Baylor College of Medicine does not view the existence of interests or relationships with commercial entities as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

If at any time during this activity you feel that there has been commercial or promotional bias, please inform us by using the commercial bias comments box in the evaluation form. Please answer the questions about balance in the CME/CE activity evaluation candidly.

The following individual(s) has/have reported no financial or other relationships with commercial entities whose products/services may relate to the educational content of this activity:

Michael Coburn, MD, Contributor, Planning Committee Member
Professor and Chair
Scott Department of Urology
Baylor College of Medicine
Houston, Texas

Disclosure: Nothing to disclose.

Ralph Conwill, Contributor, Planning Committee Member
Patient and Prostate Cancer Survivor
Franklin, Tennessee

Disclosure: Nothing to disclose.

Sarah Daugherty, PhD, Contributor, Planning Committee Member
Senior Program Officer
Patient-Centered Outcomes Research Institute (PCORI)
Washington, D.C.

Disclosure: Nothing to disclose.

Frank Domino, MD, Contributor, Planning Committee Member
Department of Family Medicine and Community Health
University of Massachusetts Medical School
Worcester, Massachusetts

Disclosure: Nothing to disclose.

Michael Fordis, M.D., Planning Committee Member
Sr. Associate Dean and Director, Center for Collaborative and Interactive Technologies
Director, The John M. Eisenberg Center for Clinical Decisions and Communications Science
Baylor College of Medicine
Houston, Texas

Disclosure: Nothing to disclose.

Vaunette Fay, PhD, Planning Committee Member
Professor of Nursing
UTHealth School of Nursing
Houston, Texas

Disclosure: Nothing to disclose.

Lisa Icard, RN, Contributor, Planning Committee Member
Nurse Manager
Scott Department of Urology
Baylor College of Medicine
Houston, Texas

Disclosure: Nothing to disclose.

Todd Kielman, PA-C, MPAS Contributor, Planning Committee Member
Instructor of Urology
Scott Department of Urology
Baylor College of Medicine
Houston, Texas

Disclosure: Nothing to disclose.

Phoung Nguyen Liebl, PharmD, Planning Committee Member
Administrative Specialist – Education and Training
Houston Methodist Hospital
Houston, Texas

Disclosure: Nothing to disclose.

The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:

Daniel Barocas, MD, MPH, Contributor
Associate Professor of Surgery and Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Research Support: The Movember Foundation
Consultant: Tolmar
Honorarium Recipient: Tolmar

Ronald Chen, MD, MPH, Contributor
Associate Professor, Department of Radiation Oncology
Associate Director, UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, North Carolina

Consultant: Accuray Inc.

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with the applicable law.

Baylor College of Medicine requires that all contributors disclose an unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products, and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

Acknowledgement of Support

This CME/CE activity is supported by a contract from the Patient-Centered Outcomes Research Institute.